These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 11295947)

  • 1. Inpatient adverse cutaneous drug eruptions and eosinophilia.
    Romagosa R; Kapoor S; Sanders J; Berman B
    Arch Dermatol; 2001 Apr; 137(4):511-2. PubMed ID: 11295947
    [No Abstract]   [Full Text] [Related]  

  • 2. Is eosinophilia helpful in diagnosing drug eruptions?
    Berman B; Villa AM
    Skinmed; 2002; 1(2):147-8. PubMed ID: 14673343
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of peripheral eosinophilia in adverse cutaneous drug reactions.
    Drago F; Cogorno L; Agnoletti AF; Parodi A
    Eur Rev Med Pharmacol Sci; 2015; 19(11):2008-9. PubMed ID: 26125262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peripheral blood eosinophil counts predict the prognosis of drug eruptions.
    Yang J; Yang X; Li M
    J Investig Allergol Clin Immunol; 2013; 23(4):248-55. PubMed ID: 23964554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct immunofluorescence for the study of cutaneous drug eruptions.
    Gibson LE; van Hale HM; Schroeter AL
    Acta Derm Venereol; 1986; 66(1):39-44. PubMed ID: 2424213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [DRESS associated with azithromycin in a child].
    Schmutz JL; Trechot P
    Ann Dermatol Venereol; 2013 Jan; 140(1):75. PubMed ID: 23328369
    [No Abstract]   [Full Text] [Related]  

  • 7. Eosinophils in severe sepsis in northern australia: do the usual rules apply in the tropics?
    Pitman MC; Anstey NM; Davis JS
    Crit Care Med; 2013 Oct; 41(10):e286-8. PubMed ID: 24060789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure to recognize and manage patients with DRESS.
    England Owen C; Stratman EJ
    Arch Dermatol; 2010 Dec; 146(12):1379. PubMed ID: 21173322
    [No Abstract]   [Full Text] [Related]  

  • 9. Negative predictive value of drug skin tests in investigating cutaneous adverse drug reactions.
    Waton J; Tréchot P; Loss-Ayav C; Schmutz JL; Barbaud A
    Br J Dermatol; 2009 Apr; 160(4):786-94. PubMed ID: 19120340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous drug eruptions: a 5-year experience.
    Gerson D; Sriganeshan V; Alexis JB
    J Am Acad Dermatol; 2008 Dec; 59(6):995-9. PubMed ID: 19022101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Adverse cutaneous drug reactions].
    Rupec RA; Boneberger S; Ruzicka T
    Dtsch Med Wochenschr; 2007 Dec; 132(50):2685-94. PubMed ID: 18058660
    [No Abstract]   [Full Text] [Related]  

  • 12. Nested case-control study investigating the diagnostic role of tissue eosinophilia in adverse cutaneous drug reactions.
    Samuelov L; Nathan A; Slutsky E; Fruchter D; Gat A; Sprecher E; Goldberg I
    J Eur Acad Dermatol Venereol; 2019 Jun; 33(6):1152-1157. PubMed ID: 30770612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recognizing the cutaneous adverse drug reaction.
    Avaliani J
    JAAPA; 2003 Feb; 16(2):20-4, 27. PubMed ID: 12666336
    [No Abstract]   [Full Text] [Related]  

  • 14. [Hypereosinophilia and hematologic analysers "formula approach"].
    Lusina D; Adam MN; Mathieu P; Balédent F; Le Pennec MP; Giacomini T
    Ann Biol Clin (Paris); 1998; 56(1):100-3. PubMed ID: 9754231
    [No Abstract]   [Full Text] [Related]  

  • 15. Eosinophilia: a diagnostic clue for nonbacterial diseases in patients with systemic inflammatory response syndrome.
    Mitre E
    Crit Care Med; 2013 Oct; 41(10):2464-5. PubMed ID: 24060788
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas.
    Tancrède-Bohin E; Ionescu MA; de La Salmonière P; Dupuy A; Rivet J; Rybojad M; Dubertret L; Bachelez H; Lebbé C; Morel P
    Arch Dermatol; 2004 Sep; 140(9):1057-61. PubMed ID: 15381544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis.
    Konikoff MR; Blanchard C; Kirby C; Buckmeier BK; Cohen MB; Heubi JE; Putnam PE; Rothenberg ME
    Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1328-36. PubMed ID: 17059896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practice Gaps. Overreliance on tissue eosinophilia in diagnosing drug eruptions.
    Swick BL
    Arch Dermatol; 2012 Feb; 148(2):194. PubMed ID: 22351818
    [No Abstract]   [Full Text] [Related]  

  • 19. Is blood eosinophilia an effective predictor of acute rejection in living donor liver transplantation?
    Kishi Y; Sugawara Y; Tamura S; Kaneko J; Akamatsu N; Togashi J; Makuuchi M
    Transpl Int; 2005 Oct; 18(10):1147-51. PubMed ID: 16162101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia.
    Ionescu MA; Rivet J; Daneshpouy M; Briere J; Morel P; Janin A
    J Am Acad Dermatol; 2005 Jan; 52(1):32-9. PubMed ID: 15627078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.